Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

'A Study of the Effect of First Line Treatment With Paclitaxel and Myocet in Combination With Herceptin on Overall Tumor Response in Patients With Metastatic or Locally Advanced Breast Cancer and HER2 Overexpression.'

NCT02015676 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02015676
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02015676 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
'A Study of the Effect of First Line Treatment With Paclitaxel and Myocet in Combination With Herceptin on Overall Tumor Response in Patients With Metastatic or Locally Advanced Breast Cancer and HER2 Overexpression.'
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2001
Completion date
September 30, 2009
Enrollment
69 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer